QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)

Merck & Co., Inc. - MRK Price Target & Analyst Ratings

$88.93
-0.26 (-0.29%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$87.36
$89.82
50-Day Range
$84.50
$94.96
52-Week Range
$70.89
$95.72
Volume
7.31 million shs
Average Volume
11.72 million shs
Market Capitalization
$225.28 billion
P/E Ratio
13.62
Dividend Yield
3.09%
Price Target
$97.44

Merck & Co., Inc. Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 18 Analyst Ratings

Consensus Analyst Price Target

$97.44
9.57% Upside
High Prediction$110.00
Average Prediction$97.44
Low Prediction$85.00
TypeCurrent
8/11/21 to 8/11/22
1 Month Ago
7/12/21 to 7/12/22
3 Months Ago
5/13/21 to 5/13/22
1 Year Ago
8/11/20 to 8/11/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
7 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$97.44$95.18$91.27$93.47
Predicted Upside9.57% Upside13.11% Upside13.73% Upside18.73% Upside
Get Merck & Co., Inc. Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.


MRK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Merck & Co., Inc. Stock vs. The Competition

TypeMerck & Co., Inc.Medical CompaniesS&P 500
Consensus Rating Score
2.61
2.71
2.50
Consensus RatingModerate BuyBuyHold
Predicted Upside8.99% Upside727.11% Upside15.31% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
901
67.09%
Underperform Votes
442
32.91%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
840
68.74%
Avg. Underperform Votes
382
31.26%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/29/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$88.00 ➝ $92.00+2.29%
7/18/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$76.00 ➝ $98.00+3.20%
7/13/2022Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$105.00 ➝ $110.00+17.52%
7/6/2022Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$89.00 ➝ $102.00+10.10%
6/27/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$95.00 ➝ $102.00+9.62%
6/24/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mara Goldstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$100.00+8.00%
6/6/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$102.00+12.72%
4/12/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$94.00 ➝ $97.00+11.97%
1/28/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$100.00 ➝ $95.00+17.90%
12/17/2021The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageConviction-Buy$93.00+22.51%
12/8/2021Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$90.00+22.93%
12/7/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Seamus Fernandez
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$98.00+33.48%
11/29/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$105.00 ➝ $85.00+7.38%
11/24/2021Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robyn Karnauskas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$92.00 ➝ $95.00+15.39%
11/18/2021BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$91.00+9.57%
11/1/2021Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$110.00+24.93%
10/10/2021Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$86.00 ➝ $92.00+14.10%
2/5/2021Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
11/10/2020Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$95.00+18.01%
8/4/2020Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
6/12/2020Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
5/4/2020Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$95.00+22.31%
10/16/2019Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Gerberry
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$90.00+6.57%
9/3/2019Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Justin Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetBuy$105.00+21.29%
(Data available from 8/11/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MRK Price Target - Frequently Asked Questions

What is Merck & Co., Inc.'s consensus rating and price target?

According to the issued ratings of 18 analysts in the last year, the consensus rating for Merck & Co., Inc. stock is Moderate Buy based on the current 8 hold ratings, 9 buy ratings and 1 strong buy rating for MRK. The average twelve-month price prediction for Merck & Co., Inc. is $97.44 with a high price target of $110.00 and a low price target of $85.00. Learn more on MRK's analyst rating history.

Do Wall Street analysts like Merck & Co., Inc. more than its competitors?

Analysts like Merck & Co., Inc. less than other Medical companies. The consensus rating for Merck & Co., Inc. is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how MRK compares to other companies.

Do MarketBeat users like Merck & Co., Inc. more than its competitors?

MarketBeat users like Merck & Co., Inc. more than other Medical companies. 67.09% of MarketBeat users gave Merck & Co., Inc. an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Is Merck & Co., Inc. being upgraded by Wall Street analysts?

Over the previous 90 days, Merck & Co., Inc.'s stock had 1 upgrade by analysts.

Does Merck & Co., Inc.'s stock price have much upside?

According to analysts, Merck & Co., Inc.'s stock has a predicted upside of 13.65% based on their 12-month price targets.

What analysts cover Merck & Co., Inc.?

Merck & Co., Inc. has been rated by Atlantic Securities, Cowen, Cowen, Daiwa Capital Markets, Mizuho, Morgan Stanley, SVB Leerink, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:MRK) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.